ABSTRACT
INTRODUCTION
The transcription factor ERG (ETS Related Gene) is overexpressed in 60-80% of prostate cancer cases [1] [2] [3] and is often attributed to a fusion between the promoter of the TMPRSS2 gene and the coding region of ERG [4, 5] . In benign prostate ERG expression levels are low and are not regulated by androgens; however in prostate cancer ERG levels are significantly higher especially if fused to the TMPRSS2 promoter which is under the control of androgens.
Expression analysis of prostate cancers reveals a wide array of genes potentially regulated by ERG to include genes involved in cell proliferation such as septin 9 (SEPT9) and metastatic pathways such as matrix metalloproteinases (e.g. MMP 3/7/9), osteopontin (OPN) and Ecadherin [3, 7, 8] .
However, the clinical importance of ERG overexpression and the presence of the TMPRSS2-ERG fusion in prostate cancer is still unclear as there are reports of a positive, negative and zero correlation with development and aggressiveness of prostate cancer. [9] [10] [11] .
Added complexity of fusion transcripts arise due to alternative splicing. Wild type ERG consists of 17 exons and expresses multiple splice isoforms [12, 13] . A significant finding has been that TMPRSS2-ERG and wild-type ERG variants exhibit differing biological properties [13, 14] . A common alternative splicing event within the central activation exon domain (CAE) of ERG is inclusion/skipping of a 72 bp exon (herein referred to as exon 11). Recent studies in vitro suggest that the inclusion of the 72bp exon (exon 11) results in increased cell proliferation and a more oncogenic phenotype [13] . Exon 10 (81bp) can also be alternatively spliced [13] .
We hypothesize that the relative proportions of ERG and its variants alter as prostate cancer progresses. If so the analysis of ERG expression and its splice variants in routine clinical samples of prostate cancer rather than just the genomic fusion, as detected by FISH, may be of value in determining the prognosis.
MATERIALS AND METHODS

Tissue samples
This study utilised tissue samples from fifty-three patients diagnosed between [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] with clinically localised hormone naïve adenocarcinoma of the prostate (Table 1) (NRES No. 09/H0102/48). Cases were selected based on the availability of cases for review and large enough tumour foci for sampling, excluding any clinically insignificant cases. Whole prostatectomy samples were fixed in neutral buffered saline for 24 hours before processing to paraffin wax and embedding in Mega Tissue Cassettes (Tissue-Tek®, Netherlands). For the study, areas of benign and invasive prostate carcinoma were identified, cored and reembedded in regular sized cassettes (Tissue-Tek®,). In order to validate the use of RT-PCR to detect the fusion, a total of 20 of the 53 cases were randomly selected for both FISH analysis and RT-PCR. Subsequently, RT-PCR and qPCR for ERG variants was performed on 53 cases.
Fluorescent in situ hybridisation (FISH) analysis.
Tri-colour FISH on paraffin-embedded prostate tumour tissue was performed using a breakapart assay designed to detect the microdeletion that occurs between TMPRSS2 and ERG at 21q22 (Kreatech, UK) as previously described [16] . Slides were counterstained using DAPI (4',6-diamidino-2-phenylindole), imaged at x100 magnification (Olympus BX41 microscope) and analysed using ISIS software.
Immunohistochemistry
Each of 40 patient samples were stained using two antibodies to ERG (EP111, Dako, UK and EPR3864; Epitomics, USA), in addition to double staining with both ERG EP111 and high molecular weight cytokeratin (34BE12, Dako, UK). All immunohistochemistry, to include antigen retrieval was performed on a BondMax™ instrument (Leica Microsystems, UK), using Bond™ Epitope Retrieval Solution. Nuclear ERG staining was visualised using the Bond™ Polymer Refine Detection system, with a diaminobenzidine chromogen. Cytoplasmic staining for high molecular weight cytokeratin staining was visualised using the Bond™ Polymer Refine Red Detection. Immunohistochemical expression of ERG was assessed as described previously, using a four tier grading system in which the intensity of nuclear staining is recorded as; negative, weakly positive, moderately positive and strongly positive [17] . The specificity of the ERG antibodies was verified by western blot analysis. In addition, we compared the staining pattern for both the EP111 clone and the previously validated EPR3864 clone [17] , both giving identical results on all cases. The EP111 clone was used for comparative analysis with the other variables, due to reduced background. Cases with invasive prostatic adenocarcinoma showing strong nuclear positivity by both clones served as positive controls. In addition, occasional endothelial cells and lymphocytes stained positively for ERG and served as internal controls. Omission of the primary antibodies, served as negative controls.
RNA isolation
For isolation of RNA from FFPE samples the RNeasy FFPE kit (Qiagen) was used as specified in the manufacturer's instructions with the following modifications: Three 5µm sections were deparaffinised in Histoclear for five minutes at 56°C followed by centrifugation and washing in ethanol. Samples underwent proteinase K digestion at 56°C overnight. RNA yields were determined by A 260 measurement using a Nanodrop spectrophotometer (Thermo Fischer Scientific, USA). Reverse transcription was performed using 500ng of RNA and M-MLV Reverse Transcriptase (Promega, UK) as per manufacturers specifications.
RT-PCR analysis
Primers to detect TMPRSS2:ERG fusion were as designed by Tomlins et al [7] .
TMPRSS2:ERG forward 5.-TAGGCGCGAGCTAAGCAGGAG-3' and TMPRSS2:ERG reverse 5'-GTAGGCACACTCAAACAACGACTGG-3'. PCR was carried out using GoTaq Hot Start Polymerase (Promega) per manufacturers recommendations.
Quantitative realtime PCR
Quantitative realtime PCR was performed using 2x Sybr green master mix (Roche, UK) and primers at 300 nmol concentration on TaqMan7300 Sequence detection System (Applied Biosystems). Primers were designed to span at least one exon boundary using the Primer Express 2.0 software (Applied biosystems, UK) and were purchased from Sigma-Genosys (Haverhill, UK) using standard qPCR cycling conditions (Table 2 ). Fold changes in expression were calculated by using a standard curve method [18] . Data were normalised to the corresponding β-actin value for each sample.
Quantitative analysis of ERG variants using LEM-PCR
To assess the relative proportion of ERG splice isoforms the linear equation method (LEM-PCR) was used, as described previously [19] . In brief, mRNA expression was quantified using Sybr Green,ERG primers (Table 2) and two linear equations (benign and cancer) generated. These equations were solved and the contributions of ERG+72/81 and ERG∆72/81 to the total value of ERG calculated. Values were then re-expressed as percentages.
Statistics
Data from experiments are presented as mean +/-standard error mean (SEM), with numbers of replicates stated in figure legends. Statistical significance between variables was tested using,the paired two-tailed student's t-test,a Kruskal-Wallis test and the Pearson Chi-Squared Test. Biochemical recurrence after radical prostatectomy was defined as a PSA value greater than or equal to 0.2ng/ml, with a second confirmatory level of PSA of >0.2 ng/ml (33) .
RESULTS
ERG mRNA expression is increased in TMPRSS2-ERG fusion positive samples.
We analysed TMPRSS2-ERG gene fusion in cancer samples using both RT-PCR and FISH in an initial 20 cases selected at random to determine concordance between the techniques Table 3) .
Relative ERG CAE splice isoform expression between benign and prostate tumours
In benign tissue the relative proportions of ERG72/∆72 and ERG81/∆81 were roughly equal (Table 4) . However, the percentage of total ERG mRNA that was accounted for by ERG∆72 (exon 11 skipped) and ERG∆81(exon 10 skipped) was significantly decreased in both T3A and T3B advanced cancer cases compared with benign tissue and there was a trend for decreased ERG∆72 and ERG∆81 in both Stage T3a and T3b advanced cancer cases when compared with T2 localised cancer ( Figure 4 and Table 4 ).
DISCUSSION
For the first time we show that it is possible to reliably detect TMPRSS2-ERG fusion isoforms in routinely collected FFPE clinical samples which have been stored at room temperature for over 10 years. FISH is the gold standard for the detection of the TMPRSS2-ERG fusion on FFPE samples. However, there are limitations to the FISH approach for TMPRSS2-ERG detection, as unlike RT-PCR, it is unable to discern between particular fusion variants of ERG, which was one of the main objectives of this study. We therefore compared FISH and RT-PCR analysis in a random subset of our cohort, in order to validate the RT-PCR approach against a known standard. We observed highly consistent results for the detection of TMPRSS2-ERG fusion by FISH and RT-PCR. There are a number of discrepancies within the literature on the clinical relevance and value of using TMPRSS2-ERG as a biomarker. We hypothesise that these discordances may be attributable to the attention focused on the TMPRSS2-ERG fusion rather than on the downstream signalling effects of ERG. For example the TMPRSS2-ERG fusion can result in non-functional ERG transcripts as a result of inclusion of premature stop codons [20, 21] . Additionally, if there is TMPRSS2-ERG fusion but androgen signalling is absent or disrupted there will be none or little ERG expression in prostate cancer cells [22] [23] [24] . As such TMPRSS2-ERG fusion status may therefore not always reflect the levels of ERG present. Thus instead of detecting a TMPRSS2-ERG fusion the accurate measurement of ERG expression may be of more prognostic relevance. Here we show that up-regulation of ERG results in increased expression of genes involved in cell proliferation (septin 9), and metastases (metalloproteinase 7, and osteopontin) (3, 7, 8) , and that high levels of ERG expression are significantly associated with seminal vesicle invasion and biochemical recurrence.
Our study also highlights the potential of immunohistochemistry as a high throughput assay for detection of overexpression of ERG in clinical cases. Immunohistochemistry has become increasingly utilised as a surrogate marker for the TMPRSS2-ERG fusion status. a [17, 25, 26] . It is important to note that whilst TMPRSS2 is the most common fusion partner for ERG, ERG can also be rearranged and fused with the SLC45A3 and NDRG1 genes. These alternative fusion partners can account for approximately 5% of ERG overexpressing prostate cancers [27] [28] [29] . As such using a TMPRSS2-ERG FISH probe in isolation could result in missing a number of prostate cancers that would have significantly elevated levels of ERG.
Like FISH, immunohistochemistry allows for marker expression to be localised in relation to tumour morphology. However, in comparison to FISH, it is relatively inexpensive, technically less demanding and readily assessed under the light microscope.
The added complexity of alternative splicing of the ERG transcript may also influence the prognostic properties of ERG. Our results suggest for the first time that there is increased retention of both the 72 bp and 81 bp exon as prostate cancer progresses. Bioinformatic studies have shown that alternative splicing is highly deregulated in cancer and that one consequence may be a reduction in exon skipping and an increase in the use of alternative 5' and 3' splice sites and intron retention [32] . However, as the retention of the 72bp exon in ERG increases cell proliferation and invasion in vitro it is highly possible that the changes in relative proportions of ERG variants may significantly contribute to the progression of prostate cancer. Future studies will focus on addressing the significance of these ERG splice variants in larger cohorts and whether these splice variants may predispose an individual to advanced prostate cancer. If found to be clinically relevant, the technology described readily lends itself to the testing of ERG and its variants on smaller needle biopsies, and the possibility of providing guidance to clinicians on the need for radical treatment. Relative proportions of ERG variants plus/minus 72bp exon 11of ERG and plus/minus 81bp exon 10 of ERG expressed as percentages of the total ERG present in benign (BN, n=12), localised (pT2, n=21) and advanced (pT3A, n=19 and pT3B, n=13) prostate cancer samples as determined using the LEM-PCR method. Table 4 .
Average values ± standard error mean (SEM) of relative amounts of ERG variants (plus/minus 72/81 bp exon) expressed as percentages of the total ERG present in benign (BN, n=12), localised (pT2, n=21) and advanced (pT3A, n=19 and pT3B, n=13) prostate cancer samples as determined using the LEM-PCR method.
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